In addition, NTRK mutant NSCLC patients exhibited increased expression of cytolytic activity markers (GZMA, PRF1), immunological checkpoints (CD274), and chemokines (CXCL9, CXCL10). This evidence concerns the gene CD274 and non-small cell lung carcinoma.